High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Diwakar Davar1,7*, Fei Ding2, Melissa Saul3, Cindy Sander1, Ahmad A. Tarhini4, John M. Kirkwood5 and Hussein A. Tawbi6

Abstract

Background: Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% respectively. Toxicity limited use to specialized centers with standardized protocols. We report on 243 patients treated at the University of Pittsburgh in a non-intensive care unit (ICU) oncology specialty setting.

Methods: Clinical and radiological data were collected on 243 patients treated between 1992 and 2015. Each HD IL-2 cycle was given over 5 days, cycles were repeated after 9 days and courses (2 cycles) were repeated every 6–9 weeks in patients with stable or responding disease, for up to 3 courses total. Influence of baseline characteristics on outcomes was assessed using Kaplan-Meier estimates and Cox proportional hazards analysis.

Results: Two hundred forty-three patients received 692 cycles (5270 doses) between 1992 and 2015. Two hundred thirty-seven patients were evaluable for response: OR rate 18.1% with CR rate 8.0%. Median overall survival (OS) 9.6 months in the entire cohort but 64.9 months in responders. Median number of cycles delivered was 2, and median number of doses per cycle was 8. Toxicity was consistent with prior reports. HD IL-2 required ICU transfers in 11 patients and 1 death was attributed to HD IL-2. Pre-treatment lactate dehydrogenase (LDH) levels correlated significantly with progression-free survival [1-2× upper limit normal (ULN) HR 1.95; >2× ULN HR 2.32] and overall survival [1-2× ULN HR 1.67; >2× ULN 2.49]. Response to HD IL-2 and site of metastatic disease also correlated significantly with progression-free and overall survival.

Conclusions: In this large series of patients spanning more than two decades, OR/CR rates with HD IL-2 were 18.1%/8.0% respectively. Toxicity data was consistent with prior reports. Pre-treatment LDH values and site(s) of metastatic disease may be useful markers to select patients at greater likelihood of benefit to HD IL-2 therapy.

Keywords: Melanoma, Metastatic, Interleukin-2, HD IL-2, Immunotherapy, CTLA-4, PD-1, BRAF, MEK

Background

Interleukin-2 is a T-cell growth factor with well characterized effects on growth and expansion of T-cell subsets particularly CD8+ T-cells and documented anti-tumor efficacy in advanced renal cancer and melanoma [1, 2]. Advanced melanoma is a disease previously considered incurable with limited treatment options and a median overall survival (OS) historically estimated at 8 to 10 months. Hitherto, high-dose interleukin-2 (HD IL-2) was the only approved immunotherapy for stage IV melanoma - based on durable long-term survival observed in a fraction of patients initially reported in a phase II study in 1994, further updated in a meta-analysis of phase II trials published in 1999 [3, 4]. In the latter study, authors reported 17 complete (6.3%) and 26 partial (9.6%) responses for an objective response (OR) rate of 15.9% in 270 treated patients. 12 of 43 initial
responders (27.9%, 10 of whom were complete responders) remained progression-free at the time of reporting, with a plateau in OS after 36 months. Commonest toxicity associated with HD IL-2 is hypotension, secondary to underlying capillary leak, reduced peripheral vascular resistance and increased cardiac output similar to a systemic inflammatory response syndrome (SIRS) syndrome that reflects the mechanism of action of IL-2. This, together with the routine use of vasopressors to maximize dose intensity contributed to a high incidence of grade 3/4 toxicities and mandated therapy in a highly regulated setting, commonly an intensive care unit (ICU).

The preceding decade has witnessed unprecedented advancements in our understanding of both the molecular drivers of melanoma tumorigenesis and mechanisms by which tumors hijack negative regulatory checkpoints to circumvent anti-tumor immunity; leading to the development of targeted inhibitors of mitogen activated protein kinase (MAPK) signal transduction pathway and negative regulatory immune checkpoints. Seven new agents including BRAF inhibitors (vemurafenib and dabrafenib), MEK inhibitor (trametinib and cobimetinib), anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor ipilimumab, programmed death 1 (PD-1) inhibitors (nivolumab and pembrolizumab) and talimogene lal<textarea hidden>....</textarea>...
Criteria in Solid Tumors (RECIST v1.1) guidelines [19]. Progression-free survival (PFS) was defined as time from start of HD IL-2 therapy to radiographic progression, clinical progression, or death, whichever occurred first. Where possible, progression was characterized as systemic-only, CNS-only or systemic and CNS. OS was defined as time from HD IL-2 initiation to death. The influence of baseline patient demographic and tumor characteristics on treatment outcomes was assessed using Cox proportional hazards analysis. Kaplan-Meier methods were used to generate estimates for PFS and OS along with corresponding 95% confidence intervals (CI). Data cutoff was defined as at 1/30/2017. All statistical analyses were performed post hoc and not adjusted for multiple testing.

Results

Patients and clinical characteristics
Between March 1992 and June 2015, data from 243 patients with American Joint Committee on Cancer (AJCC) stage IV melanoma who had received at least 1 cycle of HD IL-2 were aggregated. Baseline characteristics of all 243 patients are detailed in Table 1. 55% of patients were male with a median age of 48 years. 77% (188/243) of treated patients had cutaneous melanoma while a minority of patients had mucosal (6%, 14/243), uveal (7%, 16/243) or unknown primaries (10%, 24/243). 18% of patients had metastatic disease limited to skin, subcutaneous tissue and/or lymph nodes (M1a) while 24% of patients had pulmonary metastases (M1b) and 18% had treated central nervous system (CNS) metastases. The remaining 40% had non-lung visceral metastases. At the time of data cutoff, median duration of follow up was 9.4 months (range 0.2 to 273 months).

Toxicity profile
Two hundred forty-three patients received 5270 doses of HD IL-2 over 692 cycles in total. The number of patients who continued to receive HD IL-2 diminished with successive cycles – either for progression or toxicity. Per patient, median number of cycles received was 2, median number of total doses received was 17 and median number of doses per cycle received was 8. HD IL-2 administration resulted in 11 admissions to intensive care unit (ICU) (12/692 cycles, 1.6% incidence) most commonly for hypotension non-responsive to fluid resuscitation requiring vasopressor administration and hypoxemia secondary to pulmonary capillary leak syndrome. 1 death was attributed to HD IL-2 (0.4% mortality). Incidence of relative and/or absolute DLTs that led to termination of HD IL-2 therapy were obtained and are tabulated in Additional file 1: Table S1. Toxicity profile was consistent with prior reports of this agent. Across all cycles, oliguria (14%–58%), hypotension (14%–39%) and tachycardia (10%–21%) accounted for the majority of relative/absolute DLTs.

Table 1 Baseline characteristics

| Characteristic                        | N = 243 |
|--------------------------------------|---------|
| Median Age (range) – yr.             | 48 (14–77) |
| Sex – no. (%)                        |         |
| Male                                 | 133 (55) |
| Female                               | 110 (45) |
| Primary Site – no. (%)               |         |
| Cutaneous                            | 188 (77) |
| H&N                                  | 34 (14)  |
| LE                                   | 38 (16)  |
| UE                                   | 29 (12)  |
| Breast                               | 1 (<1)   |
| Trunk – anterior/posterior           | 74 (30)  |
| Unknown                              | 12 (5)   |
| Mucosal                              | 14 (6)   |
| Gl - anorectal                       | 3 (1)    |
| Aerodigestive                        | 3 (1)    |
| Urethral                             | 1 (<1)   |
| Vulva                                | 7 (3)    |
| Unknown                              | 24 (10)  |
| Uveal (choroid)                      | 16 (7)   |
| Other (orbit)                        | 1 (<1)   |
| Metastatic status prior to HD IL-2 – no. (%) |     |
| Skin, subcutaneous, LN (M1a)         | 43 (18)  |
| Lung (M1b)                           | 58 (24)  |
| Non-lung visceral (M1c non-CNS)      | 99 (41)  |
| CNS (M1c CNS)                        | 43 (18)  |
| LDH – no. (%)                        |         |
| Normal                               | 106 (44) |
| Abnormal                             | 137 (56) |
| 1xULN-2xULN                          | 74 (30)  |
| > 2xULN                              | 63 (26)  |
| Protocol – no. (%)                   |         |
| Standard of care (SOC)               | 193 (79) |
| HD IL-2/temozolomide                 | 30 (12)  |
| HD IL-2+/-– ziv-aflibercept (HD IL-2 alone) | 20 (8) |
| Line of therapy – no. (%)            |         |
| 1st line                             | 114 (47) |
| 2nd line                             | 83 (34)  |
| 3rd line or subsequent line          | 46 (19)  |
| Pre-HD IL-2 therapies* – no. (%)     |         |
| CTLA-4 inhibitor                     | 20 (8)   |
| PD-1 inhibitor                       | 2 (1)    |
| Other immunotherapies (including biochemotherapy) | 73 (30) |
| BRAFI/MEKi target therapy            | 3 (1)    |
| Other targeted therapy               | 13 (5)   |
**Table 1** Baseline characteristics (Continued)

| Chemotherapy          | 54 (22) |
|-----------------------|---------|
| Post-progression therapies* – no. (%) |         |
| CTLA-4 inhibitor      | 29 (12) |
| PD-1 inhibitor        | 11 (5)  |
| Other immunotherapies (including biochemotherapy) | 29 (12) |
| BRAF/MEK target therapy | 12 (5)  |
| Other targeted therapy | 5 (2)   |
| Chemotherapy          | 43 (18) |

*These categories are not mutually exclusive or exhaustive

**Response Analysis.**

Of 243 treated patients, 237 patients were evaluable for response (summarized in Table 2). Six patients were not evaluable for response. Complete responses (CR) was observed in 19 (8%) while partial responses (PR) was observed in 24 (10%) for an overall response rate (ORR) of 18% (95% CI 13%–24%). Additionally, 54 patients (23%) had stable disease for a disease control rate (DCR) of 41% (95% CI 35%–47%). Response did not differ significantly by site of primary tumor though the number of non-cutaneous uveal/mucosal primaries was low in this series (see Additional file 1: Table S2). Of the 19 patients who had a CR to HD IL-2, 3 patients subsequently relapsed, 1 of whom passed away after developing CNS disease. A 2nd patient developed an isolated biopsy-proven subcutaneous recurrence which was resected and irradiated and remains disease-free; while the 3rd patient achieved a durable remission with fourth-line PD-1 inhibitor therapy with pembrolizumab following progression on vemurafenib/Pi3K inhibitor PX-866 and CTLA-4 inhibitor ipilimumab following progression on initial HD IL-2.

We observed that the median number of doses administered differed by response category. Unsurprisingly, patients with complete/partial responses received statistically significant greater doses (median = 33), than patients with stable disease or non-responders (median = 16) (p < 0.0001).

**BRAF and NRAS mutation status** were known on 51 and 37 patients, respectively. ORR was 31% (95% CI 15%–51%) in BRAF mutant compared to 14% (3%–35%) in BRAF wild type patients. Although this difference was not statistically significant, it is consistent with prior data suggesting greater response rates in BRAF/NRAS mutant patients compared to wild type patients [20]. Given the small number of NRAS mutant patients, differential response statistics between NRAS mutant and wild type patients cannot be interpreted. Although the response rate was greater in the 1st line (23%) than in the 2nd or subsequent line (14%) – this difference was not statistically significant.

**PFS and OS analyses**

The primary analysis of 243 patients revealed a median OS of 9.6 months (95% CI, 7.4 to 11.2 months) in the entire cohort but 64.9 months (95% CI, 28.2-infinity) in responders. 1-, 2- and 3- year survival rates were 41%, 20% and 14% respectively. Median PFS was 2.8 months (95% CI 2.2–3.5) after excluding 6 patients deemed unevaluable for progression. Median follow-up time was approximately 9.4 months (range 0.2 to 273 months) at the time of data-cutoff. Primary analysis included 19 complete responders with a median follow-up time of 88.9 months (range 3.6 to 273 months). Of these, 3 patients progressed, 2 of whom were subsequently salvaged as above. Two patients with CRs passed away - though only 1 death was related to melanoma recurrence.

In comparing 1-/2-/3- year response rates for responders and non-responders, we considered two categories of responders: first excluding patients with stable disease (CR/PR only) and second including patients with stable disease (CR/PR/SD). 1-/2-/3- year OS rates for CR/PR patients were 95%/73%/63%; while 1-/2-/3- year PFS rates for CR/PR patients were 69%/52%/42% respectively. When patients with stable disease were included as responders, 1-/2-/3- year OS rates for CR/PR/SD patients were 71%/41%/31%; while 1-/2-/3- year PFS rates for CR/PR/SD patients were 35%/23%/19% respectively. Kaplan-
Meier curves for PFS and OS by response are presented in Fig. 1. Potentially prognostic factors are delineated in detail in Additional file 1: Tables S3 and S4.

Both absolute LDH elevation and the extent of LDH elevation were correlated with worse PFS compared to patients with normal LDH: 1–2× ULN (HR 1.95, 95% CI 1.41 to 2.69) and >2× ULN (HR 2.32, 95% CI 1.66 to 3.26). Relative to patients with M1a disease, patients with M1c non-CNS disease (HR 1.77, 95% CI 1.19–2.64) and M1c CNS disease (HR 1.54, 95% CI 0.97–2.45) had worse PFS. Similar trends in relation to OS were observed for pre-treatment metastatic site and extent of LDH elevation (see Fig. 2).

Efficacy of post-HD IL-2 therapies

The extent of progression (systemic vs. CNS vs. systemic and CNS) was known in 189 (78%) patients. There was no significant difference between patients who progressed with CNS metastases and those who progressed systemically ($p = 0.056$ for OS, $0.97$ for PFS). Information on post-progression therapies was available on 210 (86%) patients (see Fig. 3). Thirty-six patients were treated with CTLA-4 and/or PD-1 inhibitors while 12 patients were treated with BRAF or BRAF/MEK inhibitors. Of the 36 patients treated with CTLA-4 or PD-1 inhibitors, 7 (19%) patients remain alive with ongoing response to CTLA-4 or PD-1 blockade similar to previously published data regarding the clinical benefit of ipilimumab and pembrolizumab in HD IL-2 progressors [21]. The survival rates of patients who received CTLA-4/PD-1 checkpoint inhibitor therapy following progression on HD IL-2 (1/2/3 year survival rates of 78%/55%/32%) were similar to those published for these agents independently, suggesting that failure with HD IL-2 does not impede response to these agents [22–24]. Among the 12 patients with BRAF mutant melanoma who received BRAF/MEK inhibitors, median duration on therapy was 8.0 months – suggesting that these therapies retain their efficacy in patients who progress on HD IL-2.

Incidence and efficacy of HD IL-2 in CNS metastatic melanoma

Data pertaining to the development and management of CNS metastases were available on 240 patients in whom the incidence of CNS metastases was 38% (see Additional file 1: Table S5). There was no substantial difference in PFS between patients who did (median PFS 3.0, 95% CI 2.1–3.7) and those who did not (median PFS 2.6, 95% CI 1.9–3.7) develop CNS metastases ($p = 0.056$). A small fraction of patients with treated CNS metastases had durable long-term PFS although no significant differences were noted between patients who developed CNS metastases prior to or after HD IL-2 therapy ($p = 0.41$).

Discussion

To our knowledge, this collection of 243 melanoma patients treated with HD IL-2 is the largest institutional series to date to correlate response with PFS/OS that spanned the era before and after the introduction of effective therapies targeting driver mutations (BRAF/MEK inhibitors) and negative regulatory checkpoints (CTLA-4/PD-1 inhibitors). OS rates were compared between patients treated before and after these agents were available on clinical trials at the parent institution (2006) and following regulatory approval (2010). OS rates were unchanged in patients treated before 2006 and after 2007. However, compared to patients treated before 2010, patients treated after 2011 had improved OS ($p = 0.0053$), likely reflecting the increased availability of highly effective therapies such as CTLA-4/PD-1 and BRAF/MEK inhibitors in the community. Two other large series have studied the efficacy of HD IL-2 in patients with melanoma.
**Fig. 2** OS/PFS Analyses By LDH and Pre-Treatment Disease Burden.  

**a** and **b** Kaplan-Meier plots of progression free survival after HD IL-2 therapy in melanoma patients compared by extent of pre-treatment LDH levels (**a**) and site of metastatic disease (**b**). **c** and **d** Kaplan-Meier plots of overall survival after HD IL-2 therapy in patients compared by pre-treatment LDH levels (**c**) and site of metastatic disease (**d**). All p-values significant and unadjusted for multiple comparisons.

**Fig. 3** OS Analyses By Post HD IL-2 Therapy.  

**a** and **b** Kaplan-Meier plots of overall survival in patients who progress on HD IL-2 therapy depending on receipt of CTLA-4/PD-1 checkpoint inhibitor therapy (**a**) or BRAF/MEK inhibitors (**b**). CTLA-4/PD-1 checkpoint inhibitor therapy in HD IL-2 failures prolongs survival compared to untreated patients; with similar 1−2−3− year survival rates as those treated independently. BRAF/MEK inhibitor therapy in HD IL-2 failures produces similar PFS benefits but overall survival is not significantly improved.
melanoma and renal cell carcinoma (RCC): Providence Cancer Center (314 melanoma patients) [25] and a more recent PROCLAIMSM registry (170 melanoma patients) study [26]. Interestingly, our responses rates were similar to those in the more recently reported Alva et al. study, both of which were lower than those reported in the older Providence Cancer Center study; differences possibly explained by relative dose intensity as inferred from pressor use and patient selection factors inherent in the Providence Cancer Center study study that primarily comprised patients treated before the advent of modern therapies.

Consistent with prior reports from the Surgical Branch of the NCI and other large series, OS curves in this analysis show a clear plateau that began around 36 months following initiation of therapy [25–27]. Patients who reached this survival landmark - 14% in this analysis - appear to have a low-risk of subsequent relapse/death. Unfortunately, in the absence of ongoing surveillance imaging, it is impossible to clarify whether these patients are truly disease-free or have low-level residual tumor. Median OS (10.5 months vs. 8.0 months) and 3-year survival rates (15% and 13%) were similar for patients treated in the 1st or 2nd/subsequent lines. However post-hoc analyses do not account for potential differences of key prognostic factors between groups precluding definitive conclusions from being drawn regarding the relative benefits of using HD IL-2 in the 1st or subsequent line setting.

Presence of elevated LDH and/or visceral/CNS metastases prior to HD IL-2 were associated with poorer OS. Trend analyses suggested that the degree of LDH elevation appeared to have prognostic impact: patients with >2x ULN LDH values had significantly poorer PFS/OS than patients with 1-2x ULN LDH, who in turn did worse than patients with normal LDH. Similarly, patients with M1c (CNS and non-CNS) metastases had significantly poorer PFS/OS than patients with M1a and M1b disease. Although the presence of CNS disease was correlated with an adverse outcome, a subset of patients with treated CNS disease had durable long-term remissions consistent with prior reports of CNS activity of HD IL-2 [28, 29].

Various groups have evaluated utility of predictive biomarkers to predict benefit to HD IL-2 in RCC and melanoma. Several factors including disease burden, alveolar growth pattern and indolent disease are associated with increased rates of response to HD IL-2 in RCC although carbonic anhydrase IX appears to be more prognostic than predictive of HD IL-2 response. However, a prospective biomarker validation study (HD IL-2 “SELECT”) based on this “integrated selection” model (ISM) concluded that response rates did not significantly differ by ISM classification [30]. A similar classifier based on gene expression profiling in melanoma patients treated with HD IL-2 had previously reported greater response rates in tumors that expressed certain genes including Annexin A1, IL6R, oncostatin M, MCSF and GMCSF (class 2) compared to tumors that expressed MITF and melanocyte antigen expression (class 1) [31]; prospective validation of which is pending at this time. Given the small number of NRAS mutant patients in our series, we were not able to independently validate its favorable impact in HD IL-2 treated patients [20].

Fundamental advances in tumor immunology identified negative regulatory checkpoints (CTLA-4/PD-1) as key mediators of immune escape. Blocking antibodies to CTLA-4 (ipilimumab) and PD-1 (pembrolizumab and nivolumab) have reported durable survival rates of 20%–23% and 25%–30% at 3 years respectively [22–24]. Long term follow-up studies suggest that responses are durable especially if ongoing past 36–48 months – similar to those observed with HD IL-2 in this and other series. HD IL-2 is efficacious in a small proportion of patients who have progressed past either CTLA-4 or PD-1/PD-L1 checkpoint inhibitors [32] – an approach is being prospectively evaluated in a Cytokine Working Group study (NCT02796352).

In the current landscape, superior response rates observed with BRAF/MEK inhibitors and PD-1/CTLA-4 inhibitors have resulted in these agents supplanting HD IL-2 in the treatment of melanoma patients; particularly when coupled with the attendant complexities of HD IL-2 administration. However, identification of predictive biomarkers and/or established efficacy in a PD-1 refractory cohort may result in HD IL-2 remaining in the melanoma therapeutic armamentarium.

Separately, a modified form of aldesleukin has been developed in which conjugation with 6 releasable polyethylene glycol (PEG) chains results in a moiety (NKTR-214) that provides significant greater tumor exposure with less frequent dosing (relative to aldesleukin) with interesting in vitro activity singly and in combination with immune checkpoint blockade [33]. An early dose-finding study reported single-agent activity in RCC and melanoma with favorable safety and tolerability profile coupled with convenient outpatient administration schedule although this data has not been published [34].

In conclusion, this pooled analysis of patients with advanced melanoma treated with HD IL-2 in the modern era adds to the available data indicating durable long-term survival in responders. Median PFS/OS were 2.8 months and 9.6 months respectively. OS curves plateaued after 3 years - akin to the pattern observed in the pooled analyses of melanoma patients treated with CTLA-4 inhibitor ipilimumab and PD-1 inhibitors nivolumab and pembrolizumab, albeit at a lower fraction [22–24]. Degree of LDH elevation and M1c disease portend for poorer survival outcomes with HD IL-2 and should be considered in
evaluating ongoing/future trials of this agent and possibly other immunotherapeutic agents including checkpoint inhibitors. Although numbers are small, the fraction of responders to PD-1/CTLA-4 blockade and duration of response to BRAF (or BRAF + MEK) inhibitors following progression on HD IL-2 is consistent with other reports.

Conclusions
Immune checkpoint blockade has transformed the management of advanced melanoma with durable responses in up to 40% of treated patients. However, not all patients respond and no validated predictive biomarkers exist. HD IL-2 remains a viable treatment in melanoma and may be safely administered in a non-ICU setting. Pre-treatment disease burden and LDH elevation may select for patients at greater likelihood of benefit to HD IL-2.

Additional file

Additional file 1: Table S1. IDLT Distribution of Patients Treated with HD IL-2; Table S2. (Overall Responses to HD IL-2 Therapy in Evaluable Patients By Baseline Characteristics (N = 237)); Table S3. (PFS Analyses By Baseline Characteristics); Table S4. (OS Analyses By Baseline Characteristics); and Table S5. (Incidence of CNS Metastases (N = 240)). (DOCX 57 kb)

Abbreviations
AJCC: American Joint Committee on Cancer; CI: Confidence intervals; CNS: Central nervous system; CR: Complete response; CTLA-4: Cytotoxic T-lymphocyte antigen 4; DLT: Dose-limiting toxicities; HD IL-2: High-dose interleukin-2; ICU: Intensive care unit; IRB: Institutional Review Board; LDH: Lactate dehydrogenase; OR: Overall response; OS: Overall survival; PD: Programmed death 1; PFS: Progression-free survival; RECIST: Response Evaluation Criteria in Solid Tumors; SOC: Standard-of-care; ULN: Upper limit normal; UPCI: University of Pittsburgh Cancer Institute

Acknowledgements
The authors are grateful to “The Wiener Foundation” and “Annual 3-2-1 Ride” for their support.

Funding
This work was supported by Award Number P50 CA121973 from the National Cancer Institute (JMK).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
DD conceived of the study; participated in study design and coordination; acquired, analyzed and interpreted data; and helped to draft the manuscript. FD performed statistical analyses; analyzed and interpreted data; and helped to revise the manuscript. MS helped acquire data; and helped to revise the manuscript. CS helped acquire data; and helped to revise the manuscript. JMK conceived of the study; participated in study design and coordination; and helped to draft the manuscript. All authors read and approved the final manuscript.

Authors’ information
Nil.

Davalar Davar: Employment (nil), Leadership (nil), Stock and Other Ownership Interests (nil), Honoraria (nil), Consulting/Advisory Role (nil), Speakers’ Bureau (Incyte), Research Funding (Merck & Co.; Incyte; Checkmate Pharmaceuticals).

Fei Ding: Employment (nil), Leadership (nil), Stock and Other Ownership Interests (nil), Honoraria (nil), Consulting/Advisory Role (nil), Speakers’ Bureau (nil), Research Funding (nil).

Melissa Sault: Employment (nil), Leadership (nil), Stock and Other Ownership Interests (nil), Honoraria (nil), Consulting/Advisory Role (nil), Speakers’ Bureau (nil), Research Funding (nil).

Cindy Sander: Employment (nil), Leadership (nil), Stock and Other Ownership Interests (nil), Honoraria (nil), Consulting/Advisory Role (nil), Speakers’ Bureau (nil), Research Funding (nil).

Ahmad A. Tarhini: Employment (nil), Leadership (nil), Stock and Other Ownership Interests (nil), Honoraria (nil), Consulting/Advisory Role (Bristol-Myers Squibb; Merck & Co.), Speakers’ Bureau (nil), Research Funding (nil).

John M. Kirkwood: Employment (nil), Leadership (nil), Stock and Other Ownership Interests (nil), Honoraria (nil), Consulting/Advisory Role (Bristol-Myers Squibb; Amgen Inc.; Bristol-Myers Squibb; Merck & Co.; Novartis Pharmaceuticals Corporation).

Hussein A. Tawbi: Employment (nil), Leadership (nil), Stock and Other Ownership Interests (nil), Honoraria (nil), Consulting/Advisory Role (Novartis Pharmaceuticals Corporation), Speakers’ Bureau (nil), Research Funding (nil).

The authors are grateful to “The Wiener Foundation” and “Annual 3-2-1 Ride” for their support.

Ethics approval and consent to participate
Approval for retrospective data collection, review and publication for HD IL-2 treated melanoma patients was obtained from the University of Pittsburgh Cancer Institute (UPCI) Institutional Review Board (IRB) (IRB number PRO13050140). Patients treated on UPCI 03–137 and UPCI 10–095/NCI were consented under the respective IRB-approved protocols. Authors attest that all necessary consent was from any patients involved in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 2Department of Biostatistics; University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 3Clinical Research Informatics, University of Pittsburgh and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 4Clinical and Translational Science, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 5Department of Dermatology, and Clinical and Translational Science, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 6Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7Division of Hematology-Oncology, University of Pittsburgh Medical Center, 5117 Centre Avenue, Pittsburgh, PA 15232, USA.

Received: 7 June 2017 Accepted: 29 August 2017
Published online: 19 September 2017

References
1. Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Immunol. 1985;135:157–66.
2. Lotze MT, Maroy VL, Ethinghausen SE, Rayner AA, Sharrow SO, Seipp CA, Custer MC, Rosenberg SA. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombiant IL-2. J Immunol. 1985;135:2865–75.
3. Atkins MB, Lotze MT, Dutschke JP, Fisher R, Weiss G, Margolin K, Abrams J, Snoll M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-dose...
recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–16.

4. Rosenberg SA, Yang JC, Topalian SL, Schwartzzmuber D, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA. 1994;271:907–13.

5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebée C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Somer C, Koralek D, Eggermont AMM, Dreno B, Nolop K, Li J, Nelson BH, Hou J, Lee RJJ, Flaherty KT, McArthur GA. BRM-3 study: group improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365:1793–802.

6. Flaherty KT, Robert C, Heng SY, Puzanov I, Dummer R, Garbe C, Testori A, Maio M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Toffaleti U, Larkin J, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LL, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D. METRIC study group: improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2013;369:1747–56.

7. Long GV, Strayakovsky G, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauchisild J, Grob JJ, Chiari Sileni V, Lebée C, Mandéla M, Millward M, Arance A, Bondarenko I, Hassel JC, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, De Melo DJ, Iorio JR, Casey M, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–85.

8. Robert C, Karaszewska B, Schachter J, Rutkowski P, Maio M, Bertholet D, Alfieri A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694–703.

9. Schadendorf D, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen T-T, Berman B, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94.

10. Alva A, Daniels GA, Wolchok JD, Kefford R, Xue Y, Kwon ED, Jakubowiak A, Hwu W-J, Weber JS, Grob JJ, Larkin J, Krutovskiy M, Sznol M, Ascierto PA, Wu YL, Atkins MB. Concurrent BRAF and MEK inhibition among patients with advanced melanoma who progressed after anti-CTLA-4 treatment. JAMA Oncol. 2015;1:433–40.

11. Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Hoppe RT, Buzaid AC, Koralek D, Eggermont AMM, Flaherty KT, Sznol M, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Sznol M, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Corcoran B, McDermott D, Golub T, Atkins MB. A single center experience with high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer Res. 2009;29:4189–95.

12. Corcoran B, McDermott D, Wolchok JD. Combined BRAF and MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:1073–81.

13. Ferris RL, Rades D, Schwartz LH, Sargent D, Ford R, Dancey J, Attick SK, Gwyther S, Mooney S, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New recommendation evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

14. Paye R, Glenn L, Hoen H, Richards S, Smith JW, Lufkin R, Crocenzi TS, Urba WJ, Curti BD. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a community hospital biotherapy program. J Immunother Cancer. 2014;2:13.

15. Ribas A, Hamid O, Daud A, Hwu P, Wolchok JD, Kefford R, Xue Y, Kwon ED, Jakubowiak A, Hwu W-J, Weber JS, Grob JJ, Larkin J, Krutovskiy M, Sznol M, Ascierto PA, Wu YL, Atkins MB. Concurrent BRAF and MEK inhibition among patients with advanced melanoma who progressed after anti-CTLA-4 treatment. JAMA Oncol. 2015;1:433–40.
32. Buchbinder EI, Gunturi A, Peritt J, Dutcher J, Aung S, Kaufman HL, Einstoff MS, Milello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JL, Gonzalez R, Richart JM, Morse MA, Sullivan RJ, McDermott DF. A retrospective analysis of high-dose interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016;4:52.

33. Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, Sheng D, Liu X, Sims PW, VanderVeen LA, Ali CF, Chang TK, Konakova M, Pena RL, Kanhere RS, Kirksey YM, Ji C, Wang Y, Huang J, Sweeney TD, Kantak SS, Doberstein SK. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22:680–90.

34. Bernatchez C, Haymaker C, Tannir NM, et al. A CD122-biased agonist increases CD8+ T Cells and natural killer cells in the tumor microenvironment; making cold tumors hot with NKTR-214. Presented at: 2016 SITC Annual Meeting; November 9–13, 2016; National Harbor, MD. Abstract 387.